TRANSCODE

TransCode Therapeutics, Inc.

@transcodetherapeutics

Newton, Massachusetts
http://www.transcodetherapeutics.com
Biotechnology Research

Overview

About TransCode Therapeutics, Inc.

TransCode's goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others.

TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Important Notice: Recruitment Fraud Alert
We are aware of recruitment scams in which fraudsters pose as representatives of TransCode Therapeutics to deceive job seekers. Please note the following to protect yourself:
• We NEVER ask for payment or personal financial information during the recruitment process.
• All legitimate communication from our team will come from an official @transcodetherapeutics.com email address
• Our hiring process always includes formal interviews—either virtual or in-person.
• If you receive a job offer claiming to be from us, please do NOT respond. Report it to [email protected].

Headquarters

Newton, Massachusetts

Website

http://www.transcodetherapeutics.com

Company Size

11-50 employees

Industry

Biotechnology Research

Company Type

Public Company

Founded

2026

Specialties

Oncology, RNA, Diagnostics, Nucleic Acid Therapeutics, Orphan Disease Designation, Metastasis, Checkpoint Inhibitor, Pattern Recognition Receptor, mRNA vaccine, and CRISPR

Posts